Shilpa Medicare hit an upper-circuit limit of 10% at Rs 437.85 after consolidated net profit surged 248.7% to Rs 55.06 crore in Q3 December 2019 (Q3 FY20) as against Rs 15.79 crore reported in Q3 December 2018 (Q3 FY19).
Net sales soared 36.6% year-on-year (Y-o-Y) to Rs 236.85 crore in Q3 FY20. The Q3 figures were announced after trading hours yesterday, 10 February 2020.Profit before tax jumped 481.3% to Rs 65.45 crore Y-o-Y. Current tax expenses soared 152.8% to Rs 12.01 crore during the period under review.
Shilpa Medicare is engaged in the business of manufacturing of bulk drugs or active pharmaceutical ingredient (API) & intermediates and wind power generation. The company's segments include bulk drug/intermediates and energy. It deals with APIs, intermediates, formulations, new drug delivery systems, peptides/biotech products and specialty chemicals.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
